Melissa L. Johnson

Also affiliated with Sarah Cannon, Tennessee Oncology

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 10 papers. Top paper: “Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial”.

Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial

Nature Medicine(2023)10.1038/s41591-022-02128-z

N/A

5.6DataRank · unranked

197 citations

Brian A. Van Tine, Swethajit Biswas, Cheryl McAlpine, Melissa L. Johnson, Anthony J. Olszanski +39 more

Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results

Nature Medicine(2023)10.1038/s41591-023-02452-y

N/A

2.2DataRank · unranked

106 citations

Marcus O. Butler, Roisin E. O’Cearbhaill, David Y. Oh, Melissa L. Johnson, Kevin Zikaras +10 more

Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion–Positive Lung Cancer by Combining Selpercatinib with Crizotinib

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2278

N/A

0.724DataRank · unranked

124 citations

Melissa L. Johnson, Sarah Clifford, Romel Somwar, Jennifer Kherani, Jieun Son +23 more

SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy

Cancer Discovery(2023)10.1158/2159-8290.cd-23-0361

N/A

0.639DataRank · unranked

70 citations

Manish R. Sharma, Melissa L. Johnson, Timothy A. Yap, Shirish M. Gadgeel, Dale Nepert +20 more

NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations

Cancer Discovery(2024)10.1158/2159-8290.cd-24-0231

N/A

0.587DataRank · unranked

49 citations

Joshua C. Horan, Anupong Tangpeerachaikul, Aurélie Swalduz, Augusto Valdivia, Melissa L. Johnson +23 more

Uzatresgene autoleucel autologous T-cell monotherapy for advanced solid tumors: SURPASS, a phase 1, open-label trial

10.21203/rs.3.rs-9238113/v1

N/A

0DataRank · unranked

0 citations

Victor Moreno, Kathleen Moore, Adam Asch, Brian A. Van Tine, John Charlson +31 more

513O A phase I/II multicenter, first-in-human study of DS-7300 (B7-H3 DXd-ADC) in patients (pts) with advanced solid tumors

Annals of Oncology(2021)10.1016/j.annonc.2021.08.1035

N/A

0DataRank · unranked

6 citations

Toshihiko Doi, Sarina A. Piha‐Paul, Shiraj Sen, Toshio Shimizu, Bi‐Hua Cheng +10 more

VISTA expression and patient selection for immune-based anticancer therapy

Frontiers in Immunology(2023)10.3389/fimmu.2023.1086102

N/A

0DataRank · unranked

49 citations

Michael Molloy, Andrey Ugolkov, Reinhard W. Von Roemeling, Randolph J. Noelle, Lionel D. Lewis +4 more

Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0795

N/A

0DataRank · unranked

23 citations

Grace A. Heavey, Yanan Kuang, Emily Durlacher, Thian Kheoh, Richard C. Chao +10 more

Data from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy

(2023)10.1158/2159-8290.c.6679570

N/A

0DataRank · unranked

0 citations

Manish R. Sharma, Melissa L. Johnson, Timothy A. Yap, Shirish M. Gadgeel, Dale Nepert +20 more